-
2023.01.23
J-Pharma presented Japanese Phase II Trial of Nanvuranlat at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2023 Nanvuranlat met primary endpoint in Japanese Phase II Trial for patients with refractory, advanced biliary tract cancers
-
What's new
- J-Pharma announces Publication of the Abstract on the Japan Phase 2 study of nanvuranlat (development code: JPH203) for advanced refractory biliary tract cancer patients at the American Society of Clinical Oncology (ASCO) Annual Meeting. Nanvuranlat is an L-type amino acid transporter 1 (LAT1) inhibitor 2023/05/26
- At the 2023 ASCO Annual meeting, the latest information on the Japan Phase II study of Nanvuranlat (development code: JPH203) will be announced. Nanvuranlat is a novel L-type amino acid transporter 1 (LAT1) inhibitor for refractory biliary tract cancer patients. 2023/04/27
- Personnel Announcement 2023/03/31
- J-Pharma Announces that Mr. Haruki Kusaka, the Director of Clinical Development, has obtained an international certification as a Specialist in Medicines Development 2023/03/17
- J-Pharma presented Japanese Phase II Trial of Nanvuranlat at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2023 Nanvuranlat met primary endpoint in Japanese Phase II Trial for patients with refractory, advanced biliary tract cancers 2023/01/23
-
Monthly
- 2023.05 (1)
- 2023.04 (1)
- 2023.03 (2)
- 2023.01 (3)
- 2022.12 (2)
- 2022.05 (1)
- 2022.04 (1)
- 2022.01 (1)
- 2021.11 (1)
- 2021.07 (1)
- 2021.03 (2)
- 2021.02 (1)
- 2021.01 (2)
- 2020.07 (1)
- 2020.06 (1)
- 2019.12 (1)
- 2019.04 (1)
- 2018.12 (1)
- 2018.07 (1)
- 2018.05 (1)
- 2018.03 (1)
- 2018.01 (1)
- 2017.09 (1)
- 2016.05 (1)
- 2015.11 (1)
- 2015.04 (1)
- 2015.02 (1)